Zostavax®

Pre-clinicalTerminated

2 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Common Variable Immune Deficiency

Conditions

Common Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia

Trial Timeline

Dec 1, 2015 → Dec 1, 2017

NCT ID

NCT02960399

About Zostavax®

Zostavax® is a pre-clinical stage product being developed by Merck for Common Variable Immune Deficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT02960399. Target conditions include Common Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia.

What happened to similar drugs?

5 of 17 similar drugs in Common Variable Immune Deficiency were approved

Approved (5) Terminated (3) Active (10)

✅Pseudoephedrine/ParacetamolJohnson & JohnsonApproved

✅Dextromethorphan + PlaceboNovartisApproved

✅VivaglobinCSLApproved

✅Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + PlaceboBayerApproved

✅Aspirin (Acetylsalicylic acid, BAYE4465) + PlaceboBayerApproved

🔄Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3

🔄XylometazolineNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02960399	Pre-clinical	Terminated	Dec 1, 2015	Dec 1, 2017	Common Variable Immune Deficiency
NCT00681031	Approved	Completed	May 14, 2008	Jun 25, 2008	Herpes Zoster

Competing Products

20 competing products in Common Variable Immune Deficiency

See all competitors

Product	Company	Stage	Hype Score
Nasal Glucagon + Oxymetazoline	Eli Lilly	Phase 1	29
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + Placebo	Johnson & Johnson	Phase 2	27
Pseudoephedrine/Paracetamol	Johnson & Johnson	Approved	43
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg	Novartis	Phase 3	40
CDZ173	Novartis	Phase 2/3	38
Dextromethorphan + Placebo	Novartis	Approved	35
Xylometazoline	Novartis	Phase 3	40
N-acetylcysteine + Placebo	Novartis	Phase 2	35
Advil Congestion Relief + Advil Allergy and Congestion Relief + Paracetamol	Pfizer	Phase 3	32
pseudoephedrine hydrochloride 30 mg tablets + Placebo tablets	Pfizer	Phase 3	40
gammaglobulin	CSL	Pre-clinical	26
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)	CSL	Phase 3	40
Vivaglobin	CSL	Approved	43
Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + Placebo	Bayer	Approved	40
Aspirin (Acetylsalicylic acid, BAYE4465) + Placebo	Bayer	Approved	40
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + Placebo	Bayer	Phase 3	37
Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine + Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + Placebo	Bayer	Phase 3	37
Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + Placebo	Bayer	Phase 3	37
Acetylcysteine + Paracetamol + Phenylephrine	Sandoz Group	Phase 3	29
A-101	Aclaris Therapeutics	Phase 3	30